Intensive Care Unit and Secondary and Primary Immune Deficiency

NCT02888535 | Completed

• 1 other identifier: 2014-A01246-41
• Study Type: observational
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

Primary immune deficiencies (PID) are characterized by a failure of the immune system that is not explained by any infectious, neoplastic, or iatrogenic cause. In 2015, more than 300 different inherited rare disorders were described. The occurrence of PID in adult is rare and diagnosis may be supported by the 6 ESID signs for adult. However these warnings signs are based only on expert recommendations and do not include comprehensive symptoms of PIDs. Recurrent infections, more aggressive, are the most common mode of revelation of the PID. Less frequently, autoimmune manifestation, solid tumor, lymphoproliferation tumor, chronic granulomatosis or hemophagocytic lymphohistiocytosis syndrome (HLS) may also revealed a PID. The objective of this study was to evaluate the occurrence of unknown PID in adult admitted in critical care unit and to determinate if the investigation of PID in patients with severe infections or HLS should be routinely performed in MCIU.

Conditions

Primary Immune Deficiency Disorder

Keywords

primary immunodeficiency; secondary immunodeficiency; intensive care unit; infection; adult

Outcome Measures

Primary Outcomes (1)

• Primary objective : Number of patients with primary immune deficiency diagnosed after an admission in intensive care unit.

  A consultation in the Internal Medicine department is schduled 3 months after the hospitalization in intensive care unit to investigate an immune deficiency. This consultation consit on a physical examination and a immune testing. Immune testing included but is not limited to : Complete blood count, blood smear Immunoglobulin (Ig) isotype and IgG sub class quantitation (gram per litre) Quantitative serum complement (C3 (milligram per litre), C4 (milligram per litre), CH50 (%) and AP50 when Neisseria meningitides infection) Extensive immunophenotyping of T, B, and natural killer cells (cells/mm3) Specific antibody response to a variety of vaccine (milligram/litre) HIV serology Body computed tomography (CT) scan Lymphocytes, macrophage functional assays or genetic assay when necessary The outcome measure is the number of participants with abnormal laboratory or radiology values leading to primary immune deficiency diagnosis

  A consultation in the Internal Medicine Department is scheduled 3 months after admission in intensive care unit

Secondary Outcomes (1)

• Secondary objectives : Number of patients diagnosed for a secondary immunodeficiency after admission in intensive care unit

  A consultation in the Internal medicine department is scheduled 3 months after admisson in intensive care unit

Interventions

Internal Medicine consultation OTHER

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients aged 18 to 65, hospitalized in medical intensive care unit for a severe or opportunistic infection or an idiopathic hemophagocytic syndrome, without any known warning sign or predisposing factor, were included.

You may qualify if:

• Aged 18-65
• Hospitalized in medical intensive care unit for :
• Severe infection without pathogen identification
• Severe infection due to encapsuled pathogen
• Opportunistic infections or unusual pathogen
• Idiopathic hemophagocytic syndrome

You may not qualify if:

• primary immunodeficiency already known
• secondary immunodeficiency already known (HIV, cancer, immunosuppressive or immunomodulatory treatment, nephrotic syndrome, protein-losing enteropathy, severe malnutrition before admission, cirrhosis with hepatic failure, sickle cell disease, splenectomy and moderate chronic renal failure (clearance between 30 and 59 m² min/1.73 ml)
• local-regional factors which can be responsible for infections (history of ear, nose and throat surgery or neurosurgery, history of fracture of the skull base, cystic fibrosis, chronic respiratory insufficient)

Sponsors & Collaborators

• University Hospital, Caen: lead

Study Sites (1)

Caen University Hospital

Caen, 14000, France

Location

MeSH Terms

Conditions

Primary Immunodeficiency Diseases; Infections

Condition Hierarchy (Ancestors)

Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• Nicolas Martin Silva, MD

  University Hospital, Caen

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 6 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 27, 2016
• First Posted: September 5, 2016
• Study Start: January 1, 2015
• Primary Completion: July 1, 2017
• Study Completion: December 1, 2019
• Last Updated: February 13, 2023

Record last verified: 2017-07

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)